The digital therapeutics sector is encountering commercial headwinds as healthcare payors establish stringent reimbursement criteria for software-based medical interventions.
Reimbursement Bottlenecks
Despite FDA clearances, digital health vendors face prolonged negotiations with commercial insurers. Payors are requiring multi-year real-world evidence demonstrating cost offset prior to assigning dedicated billing codes.
Strategic Commercial Pivots
In response, several digital therapeutic providers are abandoning direct-to-consumer models, opting instead to partner with pharmaceutical majors to bundle software applications with existing drug therapies.